NEW YORK – Sydney, Australia-based Kazia Therapeutics announced on Friday that a new arm within the Glioblastoma Adaptive Global Innovative Learning Environment (GBM AGILE) study will explore the activity of its investigational drug paxalisib.
NEW YORK – Sydney, Australia-based Kazia Therapeutics announced on Friday that a new arm within the Glioblastoma Adaptive Global Innovative Learning Environment (GBM AGILE) study will explore the activity of its investigational drug paxalisib.
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.